| Literature DB >> 24446373 |
Joël Mercier1, Laurence Archen, Véronique Bollu, Stéphane Carré, Yves Evrard, Eric Jnoff, Benoît Kenda, Bénédicte Lallemand, Philippe Michel, Florian Montel, Florence Moureau, Nathalie Price, Yannick Quesnel, Xavier Sauvage, Anne Valade, Laurent Provins.
Abstract
The role of the synaptic vesicle protein 2A (SV2A) protein, target of the antiepileptic drug levetiracetam, is still mostly unknown. Considering its potential to provide in vivo functional insights into the role of SV2A in epileptic patients, the development of an SV2A positron emission tomography (PET) tracer has been undertaken. Using a 3D pharmacophore model based on close analogues of levetiracetam, we report the rationale design of three heterocyclic non-acetamide lead compounds, UCB-A, UCB-H and UCB-J, the first single-digit nanomolar SV2A ligands with suitable properties for development as PET tracers.Entities:
Keywords: epilepsy; imaging agents; levetiracetam; positron emission tomography (PET); synaptic vesicle proteins; tracers
Mesh:
Substances:
Year: 2014 PMID: 24446373 DOI: 10.1002/cmdc.201300482
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466